サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1266327

持続血糖モニタリングシステム市場：コンポーネント別、人口動態別、エンドユーザー別：世界の機会分析と産業予測、2021-2031年

Continuous Glucose Monitoring Systems Market By Component, By Demography, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日: | 発行: Allied Market Research | ページ情報: 英文 284 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.94円
持続血糖モニタリングシステム市場：コンポーネント別、人口動態別、エンドユーザー別：世界の機会分析と産業予測、2021-2031年
出版日: 2023年02月01日
発行: Allied Market Research
ページ情報: 英文 284 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

持続血糖モニタリングシステム市場は、2021年に66億2,660万米ドルと評価され、2031年には317億820万米ドルに達し、2022年から2031年にかけて17.0%のCAGRで成長すると予測されています。

持続血糖モニタリングシステム（CGM）市場は、あらゆるタイプの糖尿病患者をモニタリングする有望な糖尿病管理ツールとして台頭しました。CGMは、主に低血糖や高血糖の状態にある患者に使用されます。市場では、間質液CGM、血糖値CGM、ハイブリッド閉ループCGMなど、それぞれ独自の機能と利点を備えた複数の異なるタイプのCGMシステムが販売されています。これらのシステムは、グルコースコントロールの向上、フィンガースティック検査の必要性の低減、グルコースパターンの認識向上、生活の質の向上など、さまざまな利点を提供します。

持続血糖モニタリングシステム市場の成長は、糖尿病患者の増加、リアルタイムのグルコース測定が可能な小型化・ウェアラブルデバイスの市場開拓などの技術進歩、CGMの利点に関する患者の意識向上によってもたらされます。糖尿病の有病率の増加は、グルコースレベルを監視するためのCGMの高い採用を推進しています。CGMは、皮膚に埋め込まれたセンサーが間質液中のグルコースレベルを測定し、受信機がその測定値を表示します。例えば、国際糖尿病連合（IDF）によると、2021年には世界中で約5億3,700万人の成人が糖尿病と共存しているとされています。また、同資料では、糖尿病の成人の4人に3人以上がインドや中国などの低・中所得国に住んでいるとされています。このように、糖尿病の有病率の上昇は、CGMの需要の増加をもたらし、ひいては市場の成長に寄与しています。

さらに、政府の取り組みや償還政策の増加が、市場の成長を後押しする主な要因となっています。例えば、オーストラリア政府は、National Diabetes Services Scheme（NDSS）の一環として、1型糖尿病の有資格者に全額補助のDexcom CGMへのアクセスを提供する連続グルコースモニタリング（CGM）イニシアチブを実施しました。このイニシアチブは、1型糖尿病患者さんの生活の質を向上させ、糖尿病に伴う合併症のリスクを軽減することを目的としています。政府は、全額補助のCGMへのアクセスを提供することで、1型糖尿病患者さんがこれらのデバイスをより広く利用し、アクセスしやすくなるよう支援しています。さらに、CGMの臨床評価を行うための資金提供活動が活発化していることも、市場の成長に寄与しています。例えば、欧州委員会のHorizon 2020プログラムでは、非侵襲的なタッチグルコースモニタリング技術であるGlucoBeamの開発継続のために285万米ドルの資金を提供しました。したがって、政府によるこのようなイニシアチブは、企業が新しいCGMの調査とテストを継続することを支援し、ひいては市場の成長を後押しします。

しかし、CGMシステムのコストが高く、デバイスが複雑であるため、CGMの採用が制限され、それが市場の成長を抑制しています。

一方、米国、カナダ、世界のその他の地域などの先進国では医療機器の需要が増加しており、新興市場では成長機会が見込まれているため、予測期間中にCGMの絶大なビジネスチャンスが生まれると考えられます。

持続血糖モニタリングシステム市場は、コンポーネント、人口統計、エンドユーザー、地域に基づいて区分されます。コンポーネントに基づくと、市場はセンサーとトランスミッター＆レシーバーに分類されます。人口統計学に基づくと、市場は小児人口（≦14歳）と成人人口（＞14歳）に区分されます。エンドユーザー別に見ると、市場は病院・クリニック、ホームヘルスケア、その他に分類されます。その他には、外来環境と診断センターが含まれます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な影響要因
    • 主な投資機会
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 買い手の交渉力
    • 代替品の脅威
    • 新規参入業者の脅威
    • ライバル関係の激しさ
  • 市場力学
    • 促進要因
      • 糖尿病に苦しむ人の数の増加
      • 従来の血糖モニタリングデバイスに対するCGMの利点
      • 在宅ヘルスケアとICUにおけるCGMの高い導入率
    • 抑制要因
      • CGMに伴う悪影響
      • CGMのコストが高い
    • 機会
      • 未診断の患者数が多い
      • CGMの技術進歩
  • COVID-19による市場への影響分析

第4章 持続血糖モニタリングシステム市場：コンポーネント別

  • 概要
    • 市場規模と予測
  • センサー
    • 主要な市場動向、成長要因、機会
    • 市場規模と予測：地域別
    • 市場シェア分析：国別
  • 送信機と受信機
    • 主要な市場動向、成長要因、機会
    • 市場規模と予測：地域別
    • 市場シェア分析：国別

第5章 持続血糖モニタリングシステム市場：人口動態別

  • 概要
    • 市場規模と予測
  • 児童人口
    • 主要な市場動向、成長要因、機会
    • 市場規模と予測：地域別
    • 市場シェア分析：国別
  • 成人人口
    • 主要な市場動向、成長要因、機会
    • 市場規模と予測：地域別
    • 市場シェア分析：国別

第6章 持続血糖モニタリングシステム市場：エンドユーザー別

  • 概要
    • 市場規模と予測
  • 病院と診療所
    • 主要な市場動向、成長要因、機会
    • 市場規模と予測：地域別
    • 市場シェア分析：国別
  • 在宅ヘルスケア
    • 主要な市場動向、成長要因、機会
    • 市場規模と予測：地域別
    • 市場シェア分析：国別
  • その他
    • 主要な市場動向、成長要因、機会
    • 市場規模と予測：地域別
    • 市場シェア分析：国別

第7章 持続血糖モニタリングシステム市場：地域別

  • 概要
    • 市場規模と予測：地域別
  • 北米
    • 主要な動向と機会
    • 市場規模と予測：コンポーネント別
    • 市場規模と予測：人口動態別
    • 市場規模と予測：エンドユーザー別
    • 市場規模と予測：国別
      • 米国
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • カナダ
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • メキシコ
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
  • 欧州
    • 主要な動向と機会
    • 市場規模と予測：コンポーネント別
    • 市場規模と予測：人口動態別
    • 市場規模と予測：エンドユーザー別
    • 市場規模と予測：国別
      • ドイツ
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • フランス
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • 英国
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • イタリア
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • ロシア
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • スペイン
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • オランダ
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • ノルウェー
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • スウェーデン
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • デンマーク
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • フィンランド
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • その他欧州
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
  • アジア太平洋
    • 主要な動向と機会
    • 市場規模と予測：コンポーネント別
    • 市場規模と予測：人口動態別
    • 市場規模と予測：エンドユーザー別
    • 市場規模と予測：国別
      • 日本
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • 中国
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • インド
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • オーストラリア
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • 韓国
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • ニュージーランド
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • フィリピン
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • その他アジア太平洋地域
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
  • ラテンアメリカ・中東・アフリカ
    • 主要な動向と機会
    • 市場規模と予測：コンポーネント別
    • 市場規模と予測：人口動態別
    • 市場規模と予測：エンドユーザー別
    • 市場規模と予測：国別
      • ブラジル
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • サウジアラビア
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • 南アフリカ
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • ベネズエラ
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • アルゼンチン
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別
      • その他LAMEA
      • 主要な市場動向、成長要因、機会
      • 市場規模と予測：コンポーネント別
      • 市場規模と予測：人口動態別
      • 市場規模と予測：エンドユーザー別

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • トップ 10プレーヤーの製品マッピング
  • 競争力のあるダッシュボード
  • 競合ヒートマップ
  • トッププレイヤーのポジショニング、2021

第9章 企業プロファイル

  • Medtronic plc
  • Abbott Laboratories
  • DexCom, Inc.
  • Senseonics
  • Johnson & Johnson
  • A. Menarini Diagnostics S.r.l
  • Novo Nordisk A/S
  • GlySens Incorporated
  • Ypsomed AG
  • F. Hoffman-La Roche Ltd
図表

LIST OF TABLES

  • TABLE 01. GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 02. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR SENSORS , BY REGION, 2021-2031 ($MILLION)
  • TABLE 03. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR TRANSMITTERS AND RECEIVERS , BY REGION, 2021-2031 ($MILLION)
  • TABLE 04. GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 05. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR CHILD POPULATION, BY REGION, 2021-2031 ($MILLION)
  • TABLE 06. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR ADULT POPULATION, BY REGION, 2021-2031 ($MILLION)
  • TABLE 07. GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 08. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR HOSPITAL AND CLINICS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 09. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR HOME HEALTHCARE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 11. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. NORTH AMERICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 13. NORTH AMERICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 14. NORTH AMERICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 15. NORTH AMERICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 16. U.S. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 17. U.S. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 18. U.S. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 19. CANADA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 20. CANADA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 21. CANADA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 22. MEXICO CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 23. MEXICO CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 24. MEXICO CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 25. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 26. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 27. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 28. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 29. GERMANY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 30. GERMANY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 31. GERMANY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 32. FRANCE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 33. FRANCE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 34. FRANCE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 35. UK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 36. UK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 37. UK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 38. ITALY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 39. ITALY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 40. ITALY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 41. RUSSIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 42. RUSSIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 43. RUSSIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 44. SPAIN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 45. SPAIN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 46. SPAIN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 47. NETHERLANDS CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 48. NETHERLANDS CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 49. NETHERLANDS CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 50. NORWAY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 51. NORWAY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 52. NORWAY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 53. SWEDEN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 54. SWEDEN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 55. SWEDEN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 56. DENMARK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 57. DENMARK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 58. DENMARK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 59. FINLAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 60. FINLAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 61. FINLAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 62. REST OF EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 63. REST OF EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 64. REST OF EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 65. ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 66. ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 67. ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 68. ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 69. JAPAN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 70. JAPAN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 71. JAPAN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 72. CHINA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 73. CHINA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 74. CHINA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 75. INDIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 76. INDIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 77. INDIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 78. AUSTRALIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 79. AUSTRALIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 80. AUSTRALIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 81. SOUTH KOREA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 82. SOUTH KOREA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 83. SOUTH KOREA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 84. NEW ZEALAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 85. NEW ZEALAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 86. NEW ZEALAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 87. PHILIPPINES CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 88. PHILIPPINES CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 89. PHILIPPINES CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 90. REST OF ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 91. REST OF ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 92. REST OF ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 93. LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 94. LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 95. LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 96. LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 97. BRAZIL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 98. BRAZIL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 99. BRAZIL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 100. SAUDI ARABIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 101. SAUDI ARABIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 102. SAUDI ARABIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 103. SOUTH AFRICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 104. SOUTH AFRICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 105. SOUTH AFRICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 106. VENEZUELA  CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 107. VENEZUELA  CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 108. VENEZUELA  CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 109. ARGENTINA  CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 110. ARGENTINA  CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 111. ARGENTINA  CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 112. REST OF LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021-2031 ($MILLION)
  • TABLE 113. REST OF LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021-2031 ($MILLION)
  • TABLE 114. REST OF LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 115. MEDTRONIC PLC: KEY EXECUTIVES
  • TABLE 116. MEDTRONIC PLC: COMPANY SNAPSHOT
  • TABLE 117. MEDTRONIC PLC: PRODUCT SEGMENTS
  • TABLE 118. MEDTRONIC PLC: PRODUCT PORTFOLIO
  • TABLE 119. MEDTRONIC PLC: KEY STRATERGIES
  • TABLE 120. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 121. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 122. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 123. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 124. ABBOTT LABORATORIES: KEY STRATERGIES
  • TABLE 125. DEXCOM, INC.: KEY EXECUTIVES
  • TABLE 126. DEXCOM, INC.: COMPANY SNAPSHOT
  • TABLE 127. DEXCOM, INC.: PRODUCT SEGMENTS
  • TABLE 128. DEXCOM, INC.: PRODUCT PORTFOLIO
  • TABLE 129. DEXCOM, INC.: KEY STRATERGIES
  • TABLE 130. SENSEONICS: KEY EXECUTIVES
  • TABLE 131. SENSEONICS: COMPANY SNAPSHOT
  • TABLE 132. SENSEONICS: PRODUCT SEGMENTS
  • TABLE 133. SENSEONICS: PRODUCT PORTFOLIO
  • TABLE 134. SENSEONICS: KEY STRATERGIES
  • TABLE 135. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 136. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 137. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 138. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 139. A. MENARINI DIAGNOSTICS S.R.L: KEY EXECUTIVES
  • TABLE 140. A. MENARINI DIAGNOSTICS S.R.L: COMPANY SNAPSHOT
  • TABLE 141. A. MENARINI DIAGNOSTICS S.R.L: PRODUCT SEGMENTS
  • TABLE 142. A. MENARINI DIAGNOSTICS S.R.L: PRODUCT PORTFOLIO
  • TABLE 143. NOVO NORDISK A/S: KEY EXECUTIVES
  • TABLE 144. NOVO NORDISK A/S: COMPANY SNAPSHOT
  • TABLE 145. NOVO NORDISK A/S: PRODUCT SEGMENTS
  • TABLE 146. NOVO NORDISK A/S: PRODUCT PORTFOLIO
  • TABLE 147. GLYSENS INCORPORATED: KEY EXECUTIVES
  • TABLE 148. GLYSENS INCORPORATED: COMPANY SNAPSHOT
  • TABLE 149. GLYSENS INCORPORATED: PRODUCT SEGMENTS
  • TABLE 150. GLYSENS INCORPORATED: PRODUCT PORTFOLIO
  • TABLE 151. YPSOMED AG: KEY EXECUTIVES
  • TABLE 152. YPSOMED AG: COMPANY SNAPSHOT
  • TABLE 153. YPSOMED AG: PRODUCT SEGMENTS
  • TABLE 154. YPSOMED AG: PRODUCT PORTFOLIO
  • TABLE 155. F. HOFFMAN-LA ROCHE LTD: KEY EXECUTIVES
  • TABLE 156. F. HOFFMAN-LA ROCHE LTD: COMPANY SNAPSHOT
  • TABLE 157. F. HOFFMAN-LA ROCHE LTD: PRODUCT SEGMENTS
  • TABLE 158. F. HOFFMAN-LA ROCHE LTD: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET (2022-2031)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALCONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET
  • FIGURE 10. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR SENSORS , BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR TRANSMITTERS AND RECEIVERS , BY COUNTRY 2021-2031(%)
  • FIGURE 13. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY, 2021(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR CHILD POPULATION, BY COUNTRY 2021-2031(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR ADULT POPULATION, BY COUNTRY 2021-2031(%)
  • FIGURE 16. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2021(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR HOSPITAL AND CLINICS, BY COUNTRY 2021-2031(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR HOME HEALTHCARE, BY COUNTRY 2021-2031(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 20. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET BY REGION, 2021
  • FIGURE 21. U.S. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 22. CANADA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 23. MEXICO CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 24. GERMANY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. FRANCE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. UK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. ITALY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. RUSSIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. SPAIN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. NETHERLANDS CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. NORWAY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. SWEDEN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. DENMARK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. FINLAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. REST OF EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. JAPAN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. CHINA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. INDIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. AUSTRALIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. SOUTH KOREA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. NEW ZEALAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. PHILIPPINES CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 43. REST OF ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 44. BRAZIL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 45. SAUDI ARABIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 46. SOUTH AFRICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 47. VENEZUELA  CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 48. ARGENTINA  CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 49. REST OF LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2021-2031 ($MILLION)
  • FIGURE 50. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 51. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 52. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 53. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 54. COMPETITIVE DASHBOARD
  • FIGURE 55. COMPETITIVE HEATMAP: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET
  • FIGURE 56. TOP PLAYER POSITIONING, 2021
  • FIGURE 57. MEDTRONIC PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. MEDTRONIC PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 59. MEDTRONIC PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 60. ABBOTT LABORATORIES: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 61. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 62. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 63. DEXCOM, INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 64. DEXCOM, INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 65. JOHNSON & JOHNSON: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 66. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 67. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 68. NOVO NORDISK A/S: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 69. NOVO NORDISK A/S: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 70. NOVO NORDISK A/S: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 71. YPSOMED AG: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 72. YPSOMED AG: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 73. YPSOMED AG: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 74. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 75. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 76. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)
目次
Product Code: A01466

The continuous glucose monitoring systems market was valued at $6,626.6 million in 2021, and is estimated to reach $31,708.2 million by 2031, growing at a CAGR of 17.0% from 2022 to 2031.The continuous glucose monitoring systems (CGMs) market has emerged as a promising diabetes management tool for monitoring all types of diabetic patients. CGMs are mainly used by patients suffering from hypo and hyperglycemic conditions. There are several different types of CGM systems available in the market, each with its own set of features and benefits such as interstitial fluid CGMs, blood glucose CGMs, and hybrid closed loop CGMs. These systems offer various advantages such as improved glucose control, reduced need for fingerstick testing, increased awareness of glucose patterns, and improved quality of life.

The continuous glucose monitoring systems market growth is driven by increase in number of patients suffering from diabetes; rise in technological advancements such as the development of miniaturized and wearable devices that can provide real-time glucose readings; and increase in patient awareness about be benefits of CGMs. The rise in prevalence of diabetes propels high adoption of CGMs for monitoring glucose levels. The sensor is implanted in the layer of skin which measure glucose levels in the interstitial fluid and a receiver displays the readings. For instance, according to International Diabetes Federation (IDF), about 537 million adults are living with diabetes in 2021, across the globe. In addition, as per the same source, over 3 in 4 adults with diabetes live in low and middle-income countries such as India and China. Thus, rise in the prevalence of diabetes has resulted in increased demand for CGMs, which, in turn, contribute to the market growth.

Furthermore, increase in government initiatives and reimbursement policies are the key factors that boost the market growth. For instance, the Australian Government has implemented the continuous glucose monitoring (CGM) Initiative as part of the National Diabetes Services Scheme (NDSS) to provide access to fully subsidized Dexcom CGMs for eligible people with Type 1 diabetes. This initiative is designed to improve the quality of life for people with Type 1 diabetes and reduce the risk of complications associated with the condition. By providing access to fully subsidized CGMs, the government is helping to make these devices more widely available and accessible to people with Type 1 diabetes. Furthermore, rise in funding activities to conduct the clinical evaluations of CGMs, further contribute towards the market growth. For instance, European Commission's Horizon 2020 program provided funding of $2.85 million for the continued development of non-invasive touch glucose monitoring technology, GlucoBeam. Therefore, such initiatives taken by government supports the company to continue the research and testing of novel CGMs, which, in turn, boost the market growth.

However, the high cost of CGM systems, and complexity of devices limit the adoption of CGMs, which, in turn, restrains the market growth.

On the other hand, increased demand of medical devices in the developed countries such as the U.S., Canada, and rest of world and growth potential in emerging markets expected to create immense opportunities for CGMs during the forecast period.

The continuous glucose monitoring systems market is segmented on the basis of component, demography, end user, and region. On the basis of component, the market is classified into sensors and transmitters & receivers. On the basis of demography, the market is segmented into child population (≤14 years) and adult population (>14 years). On the basis of end user, the market is classified into hospitals & clinics, home healthcare, and others. The others include ambulatory settings and diagnostic center.

Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Spain, Italy, Netherlands, Norway, Sweden, Denmark, Finland, and rest of Europe), Asia-Pacific (India, China, Australia, Japan, South Korea, New Zealand, Philippines, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, Venezuela, Argentina, and rest of LAMEA).

Major key players that operate in the global continuous glucose monitoring systems market are: A. Menarini, Diagnostics S.r.l, Abbott Laboratories, DexCom, Inc., F. Hoffman-La Roche Ltd, GlySens Incorporated, Johnson & Johnson, Medtronic plc, Novo Nordisk A/S, Senseonics, and Ypsomed AG.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the continuous glucose monitoring systems market analysis from 2021 to 2031 to identify the prevailing continuous glucose monitoring systems market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the continuous glucose monitoring systems market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global continuous glucose monitoring systems market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Demography

  • Child Population
  • Adult Population

By End User

  • Home healthcare
  • Others
  • Hospital and Clinics

By Component

  • Transmitters and Receivers 
  • Sensors 

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Russia
    • Spain
    • Netherlands
    • Norway
    • Sweden
    • Denmark
    • Finland
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • New Zealand
    • Philippines
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Venezuela 
    • Argentina 
    • Rest of LAMEA

Key Market Players

  • Medtronic plc
  • DexCom, Inc.
  • Johnson & Johnson
  • F. Hoffman-La Roche Ltd
  • GlySens Incorporated
  • Novo Nordisk A/S
  • Abbott Laboratories
  • Senseonics
  • A. Menarini Diagnostics S.r.l
  • Ypsomed AG

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in number of people suffering from diabetes
      • 3.4.1.2. Benefits of CGMs over conventional glucose monitoring devices
      • 3.4.1.3. High adoption rate of CGMs in home healthcare and ICUs
    • 3.4.2. Restraints
      • 3.4.2.1. Adverse effects associated with CGMs
      • 3.4.2.2. High cost of CGMs
    • 3.4.3. Opportunities
      • 3.4.3.1. High undiagnosed patient population
      • 3.4.3.2. Technological advancement in CGMs
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Sensors 
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Transmitters and Receivers 
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHY

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Child Population
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Adult Population
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital and Clinics
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Home healthcare
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Component
    • 7.2.3. Market size and forecast, by Demography
    • 7.2.4. Market size and forecast, by End User
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Component
      • 7.2.5.1.3. Market size and forecast, by Demography
      • 7.2.5.1.4. Market size and forecast, by End User
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Component
      • 7.2.5.2.3. Market size and forecast, by Demography
      • 7.2.5.2.4. Market size and forecast, by End User
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Component
      • 7.2.5.3.3. Market size and forecast, by Demography
      • 7.2.5.3.4. Market size and forecast, by End User
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Component
    • 7.3.3. Market size and forecast, by Demography
    • 7.3.4. Market size and forecast, by End User
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Component
      • 7.3.5.1.3. Market size and forecast, by Demography
      • 7.3.5.1.4. Market size and forecast, by End User
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Component
      • 7.3.5.2.3. Market size and forecast, by Demography
      • 7.3.5.2.4. Market size and forecast, by End User
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Component
      • 7.3.5.3.3. Market size and forecast, by Demography
      • 7.3.5.3.4. Market size and forecast, by End User
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Component
      • 7.3.5.4.3. Market size and forecast, by Demography
      • 7.3.5.4.4. Market size and forecast, by End User
      • 7.3.5.5. Russia
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Component
      • 7.3.5.5.3. Market size and forecast, by Demography
      • 7.3.5.5.4. Market size and forecast, by End User
      • 7.3.5.6. Spain
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Component
      • 7.3.5.6.3. Market size and forecast, by Demography
      • 7.3.5.6.4. Market size and forecast, by End User
      • 7.3.5.7. Netherlands
      • 7.3.5.7.1. Key market trends, growth factors and opportunities
      • 7.3.5.7.2. Market size and forecast, by Component
      • 7.3.5.7.3. Market size and forecast, by Demography
      • 7.3.5.7.4. Market size and forecast, by End User
      • 7.3.5.8. Norway
      • 7.3.5.8.1. Key market trends, growth factors and opportunities
      • 7.3.5.8.2. Market size and forecast, by Component
      • 7.3.5.8.3. Market size and forecast, by Demography
      • 7.3.5.8.4. Market size and forecast, by End User
      • 7.3.5.9. Sweden
      • 7.3.5.9.1. Key market trends, growth factors and opportunities
      • 7.3.5.9.2. Market size and forecast, by Component
      • 7.3.5.9.3. Market size and forecast, by Demography
      • 7.3.5.9.4. Market size and forecast, by End User
      • 7.3.5.10. Denmark
      • 7.3.5.10.1. Key market trends, growth factors and opportunities
      • 7.3.5.10.2. Market size and forecast, by Component
      • 7.3.5.10.3. Market size and forecast, by Demography
      • 7.3.5.10.4. Market size and forecast, by End User
      • 7.3.5.11. Finland
      • 7.3.5.11.1. Key market trends, growth factors and opportunities
      • 7.3.5.11.2. Market size and forecast, by Component
      • 7.3.5.11.3. Market size and forecast, by Demography
      • 7.3.5.11.4. Market size and forecast, by End User
      • 7.3.5.12. Rest of Europe
      • 7.3.5.12.1. Key market trends, growth factors and opportunities
      • 7.3.5.12.2. Market size and forecast, by Component
      • 7.3.5.12.3. Market size and forecast, by Demography
      • 7.3.5.12.4. Market size and forecast, by End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Component
    • 7.4.3. Market size and forecast, by Demography
    • 7.4.4. Market size and forecast, by End User
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Component
      • 7.4.5.1.3. Market size and forecast, by Demography
      • 7.4.5.1.4. Market size and forecast, by End User
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Component
      • 7.4.5.2.3. Market size and forecast, by Demography
      • 7.4.5.2.4. Market size and forecast, by End User
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Component
      • 7.4.5.3.3. Market size and forecast, by Demography
      • 7.4.5.3.4. Market size and forecast, by End User
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Component
      • 7.4.5.4.3. Market size and forecast, by Demography
      • 7.4.5.4.4. Market size and forecast, by End User
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Component
      • 7.4.5.5.3. Market size and forecast, by Demography
      • 7.4.5.5.4. Market size and forecast, by End User
      • 7.4.5.6. New Zealand
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Component
      • 7.4.5.6.3. Market size and forecast, by Demography
      • 7.4.5.6.4. Market size and forecast, by End User
      • 7.4.5.7. Philippines
      • 7.4.5.7.1. Key market trends, growth factors and opportunities
      • 7.4.5.7.2. Market size and forecast, by Component
      • 7.4.5.7.3. Market size and forecast, by Demography
      • 7.4.5.7.4. Market size and forecast, by End User
      • 7.4.5.8. Rest of Asia-Pacific
      • 7.4.5.8.1. Key market trends, growth factors and opportunities
      • 7.4.5.8.2. Market size and forecast, by Component
      • 7.4.5.8.3. Market size and forecast, by Demography
      • 7.4.5.8.4. Market size and forecast, by End User
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Component
    • 7.5.3. Market size and forecast, by Demography
    • 7.5.4. Market size and forecast, by End User
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Component
      • 7.5.5.1.3. Market size and forecast, by Demography
      • 7.5.5.1.4. Market size and forecast, by End User
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Component
      • 7.5.5.2.3. Market size and forecast, by Demography
      • 7.5.5.2.4. Market size and forecast, by End User
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Component
      • 7.5.5.3.3. Market size and forecast, by Demography
      • 7.5.5.3.4. Market size and forecast, by End User
      • 7.5.5.4. Venezuela 
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Component
      • 7.5.5.4.3. Market size and forecast, by Demography
      • 7.5.5.4.4. Market size and forecast, by End User
      • 7.5.5.5. Argentina 
      • 7.5.5.5.1. Key market trends, growth factors and opportunities
      • 7.5.5.5.2. Market size and forecast, by Component
      • 7.5.5.5.3. Market size and forecast, by Demography
      • 7.5.5.5.4. Market size and forecast, by End User
      • 7.5.5.6. Rest of LAMEA
      • 7.5.5.6.1. Key market trends, growth factors and opportunities
      • 7.5.5.6.2. Market size and forecast, by Component
      • 7.5.5.6.3. Market size and forecast, by Demography
      • 7.5.5.6.4. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Medtronic plc
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Abbott Laboratories
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. DexCom, Inc.
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Senseonics
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Key strategic moves and developments
  • 9.5. Johnson & Johnson
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. A. Menarini Diagnostics S.r.l
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
  • 9.7. Novo Nordisk A/S
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. GlySens Incorporated
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
  • 9.9. Ypsomed AG
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. F. Hoffman-La Roche Ltd
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance